Geneva, Switzerland, May 27, 2013 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce the launch of Translational Proteomics, an online-only, open access journal devoted to transferring fundamental discoveries in the field of proteomics to clinical applications, accelerating understanding and treatment of human diseases.
Jean-Charles Sanchez, Associate Professor at the University of Geneva, Head of the Biomedical Research Proteomics Group and Director of the Proteomics Core Facility of the Faculty of Medicine, will serve as Editor-in-Chief. The journal aims to cover all areas of research in human proteomics using multi-disciplinary approaches to untangle complex disease processes, such as oncology, neurology, immunology, cardiovascular diseases, infectious diseases and any internal medical disorder. Special sections within the journal will highlight research in areas like systems biology and integrative bioinformatics, clinical proteomics and personalized medicine, comparative proteomics and drug development, medical bioinformatics and biostatistics, food and health.
"With the launch of Translational Proteomics, we want to help the scientific and medical communities overcome the challenges they face on the long path from basic research to patient care," said Professor Sanchez. "By focusing on connecting basic proteomics research to ultimate clinical applications, the journal will provide a space for publications detailing proteomics experiments, from early discovery to validation and the bedside."
"We are excited about the launch of Translational Proteomics", added Dolors Alsina, Executive Publisher at Elsevier. "This journal provides a unique platform for the publication of high-quality, multi-disciplinary studies, combining research which, until now, would have been broken into two or more specialized publications."
For more information or to submit an article, visit http://www.elsevier.com/locate/trprot
Open Access Publishing at Elsevier
Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish in over 1,500 hybrid journals as well as 39 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit http://www.elsevier.com/openaccess
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.